Evaluation of arbekacin anti-MRSA agents for adult in Japan.

There are a limited number of reports that compare the clinical ef cacy of antiMRSA agents such as arbekacin (ABK), vancomycin (VCM), teicoplanin (TEIC) and linezolid (LZD). There is a tendency for these four agents to show variation in the in ammatory response parameters, in C-reactive protein (CRP) and in white blood cell count (WBC), depending on the administration period. There was no signi cant difference among the agents in analysis of variance (ANOVA) in the group of days 1–3 (p=0.0536) but there was some signi cant difference in the group of days 4–7, as well as days 8–14 (p<0.001, p<0.01) in relative variation rate of CRP. Furthermore, we compared in more detail the groups of LZD, VCM and ABK, with a signi cant decrease of CRP, each of which showed more decrease in comparison with the group of TEIC in the period days 4–7 (p<0.01). We took 1-hr serum level after days 3–4, with the ABK treatment as the peak concentration (Cpeak). Having made nonlinear logistic regression analysis of CRP and Cpeak/MIC, we concluded that the decrease rate estimable by early in ammatory effect could be decreased to some 40%, assuming that Cpeak/MIC shows the high value within 4 days after ABK treatment.